GR3035117T3 - Use of mannose phosphates for the treatment of fibrotic disorders - Google Patents

Use of mannose phosphates for the treatment of fibrotic disorders

Info

Publication number
GR3035117T3
GR3035117T3 GR20000402805T GR20000402805T GR3035117T3 GR 3035117 T3 GR3035117 T3 GR 3035117T3 GR 20000402805 T GR20000402805 T GR 20000402805T GR 20000402805 T GR20000402805 T GR 20000402805T GR 3035117 T3 GR3035117 T3 GR 3035117T3
Authority
GR
Greece
Prior art keywords
pct
treatment
mannose
fibrotic disorders
phosphates
Prior art date
Application number
GR20000402805T
Other languages
Greek (el)
Inventor
Mark William James Ferguson
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of GR3035117T3 publication Critical patent/GR3035117T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PCT No. PCT/GB93/00541 Sec. 371 Date Aug. 24, 1994 Sec. 102(e) Date Aug. 24, 1994 PCT Filed Mar. 16, 1993 PCT Pub. No. WO93/18777 PCT Pub. Date Sep. 30, 1993.Mannose-6- and 1-phosphates and their pharmaceutically acceptable salts and bioprecursors thereof are useful in the treatment of fibrotic disorders. They accelerate wound healing and the 6-phosphate prevents or mitigates scar formation. The invention includes particular, appropriate formulations of the mannose phosphate.
GR20000402805T 1992-03-17 2000-12-19 Use of mannose phosphates for the treatment of fibrotic disorders GR3035117T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929205800A GB9205800D0 (en) 1992-03-17 1992-03-17 Treatment of fibrotic disorders
PCT/GB1993/000541 WO1993018777A1 (en) 1992-03-17 1993-03-16 Use of mannose phosphates for the treatment of fibrotic disorders

Publications (1)

Publication Number Publication Date
GR3035117T3 true GR3035117T3 (en) 2001-03-30

Family

ID=10712310

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000402805T GR3035117T3 (en) 1992-03-17 2000-12-19 Use of mannose phosphates for the treatment of fibrotic disorders

Country Status (18)

Country Link
US (1) US5520926A (en)
EP (1) EP0728006B1 (en)
JP (1) JP3930556B2 (en)
AT (1) ATE196847T1 (en)
AU (1) AU667887B2 (en)
CA (1) CA2130805C (en)
DE (1) DE69329559T2 (en)
DK (1) DK0728006T3 (en)
ES (1) ES2151903T3 (en)
GB (2) GB9205800D0 (en)
GR (1) GR3035117T3 (en)
IL (1) IL105079A (en)
NO (1) NO306808B1 (en)
NZ (1) NZ249915A (en)
PT (1) PT728006E (en)
SG (1) SG49899A1 (en)
WO (1) WO1993018777A1 (en)
ZA (1) ZA931869B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
SE9403137D0 (en) * 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
US6566339B1 (en) 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB9516012D0 (en) * 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
GB9616896D0 (en) * 1996-08-12 1996-09-25 British Tech Group Pharmaceutical compositions
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
DE19758059C2 (en) * 1997-12-29 2001-10-04 Thorsten Marquardt Use of mannose to combat protein loss enteropathy
US7255883B2 (en) * 2000-06-23 2007-08-14 Healagenics, Inc. Agent for reduction of scar formation by using wound alkalinization
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US20030031689A1 (en) * 2001-08-09 2003-02-13 Thomas Mammone Method of skin exfoliation
US6822033B2 (en) 2001-11-19 2004-11-23 United States Gypsum Company Compositions and methods for treating set gypsum
AU2003209308A1 (en) * 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
BR0309890A (en) * 2002-05-09 2005-05-10 Medigenes Pharmaceutical composition containing blood plasma or blood serum used in the treatment of lesions, as well as its method and application process
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
KR100492913B1 (en) * 2002-08-23 2005-06-03 주식회사 태평양 Skin external compositions for reducing skin adverse reaction induced by skin irritant and sensitizer
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
JP4634027B2 (en) * 2003-05-16 2011-02-16 花王株式会社 Vitamin D-like active substitute
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
JP5481028B2 (en) * 2004-10-13 2014-04-23 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Methods for treating or preventing virus-related lymphoproliferative disorders
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
JP5602365B2 (en) 2005-10-25 2014-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ Methods and compositions for treating Marfan syndrome and related diseases.
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
DK2083863T3 (en) 2006-10-03 2015-06-22 Genzyme Corp ANTIBODIES AGAINST TGF-BETA TO USE IN TREATMENT OF BABIES WITH RISK OF DEVELOPMENT OF SOURCOPULMONAL DYSPLASY
US8070895B2 (en) 2007-02-12 2011-12-06 United States Gypsum Company Water resistant cementitious article and method for preparing same
US8329308B2 (en) 2009-03-31 2012-12-11 United States Gypsum Company Cementitious article and method for preparing the same
GB0910078D0 (en) 2009-06-11 2009-07-22 Renovo Ltd Uses of mannose-6-phosphate
GB0916333D0 (en) 2009-09-17 2009-10-28 Renovo Ltd Improvement of tendon repair
GB0916334D0 (en) * 2009-09-17 2009-10-28 Renovo Ltd Inhibition of tendon adhesions
ES2584433T3 (en) 2010-03-12 2016-09-27 Genzyme Corporation Combination therapy to treat breast cancer
WO2012087434A2 (en) * 2010-11-05 2012-06-28 Healthypharma, Llc Use of phosphoric acid
KR20130131414A (en) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 Ips cells and method for generating same
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
JP6218229B2 (en) 2011-12-28 2017-10-25 京都府公立大学法人 Normalization of corneal endothelial cell culture
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2023172636A1 (en) * 2022-03-08 2023-09-14 University Of Mississippi Medical Center Articles and methods for improved tissue healing
CN115260256A (en) * 2022-07-22 2022-11-01 河南中医药大学 Mannose phosphorylation derivative and preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756953A (en) * 1969-10-02 1971-04-01 Merck & Co Inc POTENTIALIZATION OF ANTIBIOTICS
JPS5631156B2 (en) * 1973-09-25 1981-07-20
IT1170618B (en) * 1981-01-13 1987-06-03 Foscama Biomed Chim Farma PHARMACOLOGICAL PREPARATION OF SIO-1,6-DIPHOSPHATE FRUIT WITH THERAPEUTIC ACTION IN BURNED PATIENTS
US4703040A (en) * 1985-04-03 1987-10-27 Markov Angel K Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
DE3686022D1 (en) * 1985-10-22 1992-08-20 Silvetti Sen MONOSACCHARIDE CONTAINING COMPOSITION FOR HEALING Wounds.
US4889844A (en) * 1985-10-22 1989-12-26 Silvetti Sr Anthony N Fructose containing wound healing preparation
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
JPS62243675A (en) * 1986-04-15 1987-10-24 Kao Corp Ph buffering
WO1990001938A1 (en) * 1988-08-19 1990-03-08 The Australian National University Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
GB8917414D0 (en) * 1989-07-29 1989-09-13 Translift Material Handling Narrow aisle lift truck
EP0494264B1 (en) * 1989-09-29 1997-06-18 La Jolla Cancer Research Foundation Inhibiting transforming growth factor to prevent accumulation of extracellular matrix
SE8904354D0 (en) * 1989-12-21 1989-12-21 Matti Siren A PHARMACEUTICAL COMPOSITION
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JPH0558868A (en) * 1991-08-27 1993-03-09 Kao Corp Hydrophilic ultraviolet light absorber and cosmetic containing the same
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
JPH09155319A (en) * 1995-12-13 1997-06-17 Takeo Tsutsui Method for processing for making heavy metal-containing incineration ash, etc., and shredder dust pollution-free and manufacture of reuse material

Also Published As

Publication number Publication date
GB9205800D0 (en) 1992-04-29
ZA931869B (en) 1994-09-16
ATE196847T1 (en) 2000-10-15
WO1993018777A1 (en) 1993-09-30
CA2130805C (en) 2003-06-24
EP0728006B1 (en) 2000-10-11
IL105079A0 (en) 1993-07-08
EP0728006A1 (en) 1996-08-28
CA2130805A1 (en) 1993-09-30
DE69329559D1 (en) 2000-11-16
NO943451L (en) 1994-09-16
US5520926A (en) 1996-05-28
NO306808B1 (en) 1999-12-27
PT728006E (en) 2001-04-30
AU3759093A (en) 1993-10-21
AU667887B2 (en) 1996-04-18
NO943451D0 (en) 1994-09-16
DE69329559T2 (en) 2001-05-31
JP3930556B2 (en) 2007-06-13
GB9305344D0 (en) 1993-05-05
ES2151903T3 (en) 2001-01-16
SG49899A1 (en) 1998-06-15
NZ249915A (en) 1996-08-27
IL105079A (en) 1998-06-15
GB2265310A (en) 1993-09-29
GB2265310B (en) 1996-09-25
DK0728006T3 (en) 2000-10-30
JPH07504909A (en) 1995-06-01

Similar Documents

Publication Publication Date Title
GR3035117T3 (en) Use of mannose phosphates for the treatment of fibrotic disorders
NO307027B1 (en) Use of riluzole in the treatment of neurological lesions related to traumatic injuries
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
PT944389E (en) Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
TW238305B (en)
GB9521608D0 (en) Pharmaceutical composition
HK1053264A1 (en) Phosphonate analogues of mannose-6-phosphate and their use in the treatment of wounds and fibrotic disorders.
EP0744176A3 (en) Methods for inhibiting bone loss
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline